Paul van der Valk

5.7k citations

118 papers · 3.6k indexed · h-index 34

Oncology top 2%
Pulmonary and Respiratory Medicine top 2%
Molecular Biology top 10%
Physiology top 5%
Pathology and Forensic Medicine top 2%

Co-authors: Job van der Palen Jan P. A. Baak Johannes S. de Jong Gerhard Zielhuis Cees van Herwaarden Evelyn M. Monninkhof P. J. van Diest Giuseppe Giaccone
Topics: Chronic Obstructive Pulmonary Disease (COPD) Research (32 papers)Asthma and respiratory diseases (14 papers)Hemophilia Treatment and Research (12 papers)
Cited by: Issues, ethics and legal aspects Oncology Pulmonary and Respiratory Medicine
Journals: The Lancet The Journal of Experimental Medicine Journal of Clinical Oncology
Partner nations: Netherlands Australia United States

In The Last Decade

Paul van der Valk

113 papers receiving 3.5k citations

Peers

Countries citing papers authored by Paul van der Valk

Since Specialization

Citations

This map shows the geographic impact of Paul van der Valk's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Paul van der Valk with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Paul van der Valk more than expected).

Fields of papers citing papers by Paul van der Valk

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Paul van der Valk. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Paul van der Valk. The network helps show where Paul van der Valk may publish in the future.

Co-authorship network of co-authors of Paul van der Valk

This figure shows the co-authorship network connecting the top 25 collaborators of Paul van der Valk. A scholar is included among the top collaborators of Paul van der Valk based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Paul van der Valk. Paul van der Valk is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Clotting factor activity levels and bleeding risk in people with haemophilia playing sports 2023 ·Haemophilia ·(unknown),Ellen Kemler,(unknown),Merel A. Timmer,(unknown),Karin P. M. van Galen,Idske C. L. Kremer Hovinga,Paul van der Valk,Lize F. D. van Vulpen,Roger E. G. Schutgens,Casper F. van Koppenhagen,Janjaap van der Net,Kathelijn Fischer	5
2	Can motor proficiency testing predict sports injuries and sports‐induced bleeds in people with haemophilia? 2023 ·Haemophilia ·(unknown),(unknown),Merel A. Timmer,(unknown),Karin P. M. van Galen,(unknown),Paul van der Valk,(unknown),Roger E. G. Schutgens,(unknown),Janjaap van der Net,Kathelijn Fischer	1
3	Transition readiness among adolescents and young adults with haemophilia in the Netherlands: Nationwide questionnaire study 2023 ·Haemophilia ·(unknown),(unknown),Marjon H. Cnossen,Cees Smit,Lize F. D. van Vulpen,Paul van der Valk,Jeroen Eikenboom,Floor Heubel-Moenen,(unknown),Paula F. Ypma,Laurens Nieuwenhuizen,Michiel Coppens,Saskia E.M. Schols,Britta A. P. Laros‐van Gorkom,Frank W.G. Leebeek,M.H.E. Driessens,Frits R. Rosendaal,Johanna G. van der Bom,Karin Fijnvandraat,Samantha C. Gouw	0
4	New Inhibitors in the Ageing Population: A Retrospective, Observational, Cohort Study of New Inhibitors in Older People with Hemophilia 2021 ·Thrombosis and Haemostasis ·Jan Astermark,Cihan Ay,Manuela Carvalho,Roseline d’Oiron,Philippe de Moerloose,Gerard Dolan,Pierre Fontana,Cédric Hermans,Pål André Holme,Όλγα Κατσαρού,Gili Kenet,Robert Klamroth,Maria Elisa Mancuso,(unknown),Ramiro Núñez,Ingrid Pabinger,Robert C. Tait,Paul van der Valk	0
5	Reduced cardiovascular morbidity in patients with hemophilia: results of a 5-year multinational prospective study 2021 ·Blood Advances ·Paul van der Valk,Michael Makris,Kathelijn Fischer,Robert C. Tait,Pratima Chowdary,Peter W. Collins,Karina Meijer,Lize F. D. van Vulpen,Eveline P. Mauser‐Bunschoten,Roger E. G. Schutgens	18
6	Adherence to an eHealth Self-Management Intervention for Patients with Both COPD and Heart Failure: Results of a Pilot Study 2021 ·International Journal of COPD ·(unknown),(unknown),Job van der Palen,Michiel Eijsvogel,Paul van der Valk,Gerard C.M. Linssen,(unknown),(unknown),Monique Tabak,Tanja Effing,Anke Lenferink	17
7	Real-Life Pharmacokinetics of rFVIII-Fc and rFIX-Fc 2020 ·SHILAP Revista de lepidopterología ·(unknown),Kathelijn Fischer,(unknown),Paul van der Valk,Idske C. L. Kremer Hovinga,Lize F. D. van Vulpen,Roger E. G. Schutgens	2
8	Patients with underuse or overuse of inhaled corticosteroids have different perceptions and beliefs regarding COPD and inhaled medication 2018 ·Patient Preference and Adherence ·(unknown),Marjolein Brusse‐Keizer,Paul van der Valk,Kris L. L. Movig,Job van der Palen,Christina Bode	6
9	Blood eosinophilia as a marker of early and late treatment failure in severe acute exacerbations of COPD 2017 ·Respiratory Medicine ·(unknown),(unknown),René Lutter,Johannes M. A. Daniels,Paul van der Valk,Margreet Schoorl,Huib A.M. Kerstjens,Tjip S. van der Werf,Wim Boersma	36
10	Associations between comorbid load and baseline characteristics in COPD patients with comorbidities: Preliminary results 2014 ·European Respiratory Journal ·Anke Lenferink,Job van der Palen,Peter Frith,Paul van der Valk,Tanja Effing	1
11	Comparing The Ease Of Use, Preference And Satisfaction Of Accuhaler/Diskus And Elpenhaler In Patients With Asthma Or Chronic Obstructive Pulmonary Disease 2013 ·American Journal of Respiratory and Critical Care Medicine ·Job van der Palen,Paul van der Valk,(unknown),Karin Groothuis‐Oudshoorn,Marjolein Brusse‐Keizer	1
12	Preference, satisfaction and errors with two dry powder inhalers in patients with COPD 2013 ·Expert Opinion on Drug Delivery ·Job van der Palen,(unknown),(unknown),Paul van der Valk,(unknown),Laura Padullés,Beatriz Seoane,Ludmyla Rekeda,Esther García Gil	58
13	Sphingosine 1-phosphate receptor 5 mediates the immune quiescence of the human brain endothelial barrier 2012 ·Journal of Neuroinflammation ·(unknown),Melissa A Lopes Pinheiro,Gijs Kooij,Kim Lakeman,Bert van het Hof,(unknown),Dirk Geerts,Jack van Horssen,Paul van der Valk,(unknown),Eric Ronken,Arie Reijerkerk,Helga E. de Vries	104
14	[Specialization versus generalization in pathology]. 2007 ·PubMed ·Paul van der Valk	2
15	Effect of Discontinuation of Inhaled Corticosteroids in Patients with Chronic Obstructive Pulmonary Disease: The COPE Study 2002 ·American Journal of Respiratory and Critical Care Medicine ·Paul van der Valk,Evelyn M. Monninkhof,Job van der Palen,Gerhard Zielhuis,Cees van Herwaarden	217
16	Expression of growth factors, growth inhibiting factors, and their receptors in invasive breast cancer. I: An inventory in search of autocrine and paracrine loops 1998 ·The Journal of Pathology ·Johannes S. de Jong,P. J. van Diest,Paul van der Valk,Jan P. A. Baak	145
17	Expression of drug resistance proteins in breast cancer, in relation to chemotherapy 1997 ·International Journal of Cancer ·Sabine C. Linn,Herbert M. Pinedo,J van Ark-Otte,Paul van der Valk,Klaas Hoekman,Aafke H. Honkoop,Jan B. Vermorken,Giuseppe Giaccone	7
18	Adenolymphoma and non-Hodgkin's lymphoma of the salivary glands and oral cavity in immunocompetent patients are not associated with latent Epstein-Barr virus 1997 ·Oral Oncology ·Eppo B. Wolvius,Natasha Jiwa,Paul van der Valk,A Horstman,I. van der Waal	8
19	Expression of drug resistance proteins in breast cancer, in relation to chemotherapy 1997 ·International Journal of Cancer ·Sabine C. Linn,Herbert M. Pinedo,J van Ark-Otte,Paul van der Valk,Klaas Hoekman,Aafke H. Honkoop,Jan B. Vermorken,Giuseppe Giaccone	84
20	Treatment with tumour infiltrating lymphocytes and interleukin-2 in patients with metastatic melanoma: A pilot study 1992 ·Biotherapy ·Johanna W. Baars,(unknown),R.J. Scheper,Bert Flier,Herman Bril,Paul van der Valk,Herbert M. Pinedo,John Wagstaff	8

About Paul van der Valk

Paul van der Valk is a scholar working on Issues, ethics and legal aspects, Hematology and Pulmonary and Respiratory Medicine, having authored 118 papers that have together received 3.6k indexed citations. Recurring topics across this work include Chronic Obstructive Pulmonary Disease (COPD) Research (32 papers), Asthma and respiratory diseases (14 papers) and Hemophilia Treatment and Research (12 papers). The work is most often cited by research in Issues, ethics and legal aspects (83 citations), Oncology (1.2k citations) and Pulmonary and Respiratory Medicine (1.1k citations). Paul van der Valk has collaborated with scholars based in Netherlands, Australia and United States. Frequent co-authors include Job van der Palen, Jan P. A. Baak, Johannes S. de Jong, Gerhard Zielhuis, Cees van Herwaarden, Evelyn M. Monninkhof, P. J. van Diest, Giuseppe Giaccone, Paul J. van Diest and Rik J. Scheper. Their work appears in journals such as The Lancet, The Journal of Experimental Medicine and Journal of Clinical Oncology.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact